MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Biphasic or Mixed

Combination of epithilioid and sarcomatoid mesothelioma types. Approximately 20-35% of cases are classified as mixed or biphasic mesothelioma.

Soluble Mesothelin-Related Peptides to Monitor Recurrence After Resection of Pleural Mesothelioma

Comments Off on Soluble Mesothelin-Related Peptides to Monitor Recurrence After Resection of Pleural Mesothelioma

Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial

Journal of Clinical Oncology 2017 September 11 [Epub ahead of print] [Link] Grosso F, Steele N, Novello S, Nowak AK, Popat S, Greillier L, John T, Leighl NB, Reck M, Taylor P, Planchard D, Sørensen JB, Socinski MA, von Wangenheim U, Loembé AB, Barrueco J, Morsli N, Scagliotti G Abstract Purpose LUME-Meso is a phase […]

Comments Off on Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial

JQ1, a BET inhibitor, synergizes with cisplatin and induces apoptosis in highly chemoresistant malignant pleural mesothelioma cells

Current Cancer Drug Targets 2017 June 23 [Epub ahead of print] [Link] Zanellato I, Colangelo D, Osella D Abstract Malignant pleural mesothelioma (MPM) is an asbestos-associated tumor with poor prognosis and few therapeutic options. JQ1, a selective antagonist of BRD4, modulates transcription of oncogenes, including MPM chemoresistance-associated c-Myc and Fra-1. We investigated if JQ1 could […]

Comments Off on JQ1, a BET inhibitor, synergizes with cisplatin and induces apoptosis in highly chemoresistant malignant pleural mesothelioma cells

Synergistic targeting of malignant pleural mesothelioma cells by MDM2 inhibitors and TRAIL agonists

Oncotarget 2017 May 11 [Epub ahead of print] [Link] Urso L, Cavallari I, Silic-Benussi M, Biasini L, Zago G, Calabrese F, Conte PF, Ciminale V, Pasello G Abstract Malignant Pleural Mesothelioma (MPM) is a chemoresistant tumor characterized by low rate of p53 mutation and upregulation of Murine Double Minute 2 (MDM2), suggesting that it may […]

Comments Off on Synergistic targeting of malignant pleural mesothelioma cells by MDM2 inhibitors and TRAIL agonists

Comparison of outcomes following a cytological or histological diagnosis of malignant mesothelioma.

British Journal of Cancer 2017 March 14 [Epub 2017 February 14] [Link] Muruganandan S, Alfonso H, Franklin P, Shilkin K, Segal A, Olsen N, Reid A, de Klerk N, Musk AB, Brims F Abstract BACKGROUND: Survival with the epithelioid subtype of malignant mesothelioma (MM) is longer than the biphasic or sarcomatoid subtypes. There is concern […]

Comments Off on Comparison of outcomes following a cytological or histological diagnosis of malignant mesothelioma.

Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1-Deficient Thoracic Cancers.

Journal of Clinical Oncology 2017 April [Epub ahead of print] [Link] Beddowes E, Spicer J, Chan PY, Khadeir R, Corbacho JG, Repana D, Steele JP, Schmid P, Szyszko T, Cook G, Diaz M, Feng X, Johnston A, Thomson J, Sheaff M, Wu BW, Bomalaski J, Pacey S, Szlosarek PW Abstract Purpose Pegylated arginine deiminase (ADI-PEG […]

Comments Off on Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1-Deficient Thoracic Cancers.

Non-Hodgkin Lymphoma and Pleural Mesothelioma in a Person Exposed to Asbestos

Turk Patologi 2017 February [Epub ahead of print] [Link] Bianchi C, Bianchi T Abstract Non-Hodgkin lymphoma and pleural mesothelioma may co-exist in the same patient. A large cell non-Hodgkin lymphoma of the inguinal lymph nodes was diagnosed in a 73-year-old woman. The patient was treated by chemotherapy. She did not receive radiotherapy. The patient had […]

Comments Off on Non-Hodgkin Lymphoma and Pleural Mesothelioma in a Person Exposed to Asbestos

Is less also better? A single-institution experience on treatment of early stage Malignant Pleural Mesothelioma.

European Journal of Surgical Oncology 2017 February [Epub ahead of print] [Link] Bertoglio P1, Ambrogi MC, Chella A, Aprile V, Dini P, Korasidis S, Fanucchi O, Mussi A Abstract OBJECTIVES: No clear evidence of which surgical procedure should be performed for early stage mesothelioma is available to date. We analyzed our 10-year experience in the […]

Comments Off on Is less also better? A single-institution experience on treatment of early stage Malignant Pleural Mesothelioma.

Amount of Epithelioid Differentiation Is a Predictor of Survival in Malignant Pleural Mesothelioma

The Annals of Thoracic Surgery 2017 March [Epub 2016 October] [Link] Vigneswaran WT, Kircheva DY, Ananthanarayanan V, Watson S, Arif Q, Celauro AD, Kindler HL, Husain AN Abstract BACKGROUND: Macroscopic complete surgical resection with adjuvant chemotherapy can provide a survival advantage in patients with malignant pleural mesothelioma (MPM). Patients with nonepithelioid histology are largely excluded […]

Comments Off on Amount of Epithelioid Differentiation Is a Predictor of Survival in Malignant Pleural Mesothelioma

Kdm6a and Kdm6b: Altered expression in malignant pleural mesothelioma

International Journal of Oncology 2017 February 9 [Epub ahead of print] [Link] Cregan S, Breslin M, Roche G, Wennstedt S, MacDonagh L, Albadri C, Gao Y, O’Byrne KJ, Cuffe S, Finn SP, Gray SG Abstract Malignant pleural mesothelioma (MPM) is a rare aggressive cancer of the pleura primarily associated with prior exposure to asbestos. The […]

Comments Off on Kdm6a and Kdm6b: Altered expression in malignant pleural mesothelioma